Article citationsMore>>

Sinert, R., Levy, P., Bernstein, J.A., Body, R., Sivilotti, M.L., Moellman, J., et al. (2017) Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema. The Journal of Allergy and Clinical Immunology: In Practice, 5, 1402-1409.e3.
https://doi.org/10.1016/j.jaip.2017.03.003

has been cited by the following article:

• TITLE: Angiotensin-Converting Enzyme Inhibitor Induced Angioedema Occurring after 8 Years of Taking Lisinopril: A Case Report

  AUTHORS: Wade Jodeh, Gregory Stone

  KEYWORDS: Angioedema, Angiotensin Converting Enzyme Inhibitor, Lisinopril, Eight Years

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.9 No.5, April 22, 2020

  ABSTRACT: Angiotensin-converting enzyme inhibitor induced angioedema (AIIA) can vary from mild to life-threatening. A vast majority of cases of AIIA occur within a month of starting an angiotensin-converting enzyme-inhibitor (ACE-I). We present a 48-year-old male who presented with respiratory failure secondary to AIIA, after being on lisinopril for over 8 years. He had no previous complications secondary to lisinopril and aside from smoking, carried no risk factors for AIIA. Despite conventional treatment for angioedema, he had a prolonged stay in the Medical Intensive Care Unit (MICU). Following discharge, there hasn’t been a recurrence of AIIA since the discontinuation of lisinopril. The case is intended to caution that AIIA remains possible even late into a chronic regimen of ACE-I. This is a risk that shouldn’t be neglected, even with sparse risk factors or longer duration of ACE-I use. Conventional treatment is not currently in line with proposed etiologies of AIIA. We advocate for more clinical trials involving pharmaceutical agents targeting bradykinin accumulation.